DRESDEN, Germany--(BUSINESS WIRE)--Cenix BioScience GmbH (Dresden), the leading specialist in advanced RNA interference (RNAi)-based research services, today announced that it has signed a framework research agreement to support CellCentric Ltd, a biotechnology company unlocking epigenetic control mechanisms, through cell-based validation of novel therapeutic drug targets for oncology.
